Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.

  title={Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.},
  author={Alberto Papi and David B. Price and Joaqu{\'i}n Sastre and Kirsten Kaiser and Mark Lomax and Tammy McIver and Sanjeeva Dissanayake},
  journal={Respiratory medicine},
  volume={109 2},

Figures and Tables from this paper

Short-Term Growth During Treatment with Inhaled Fluticasone Propionate/Formoterol, Fluticasone and Beclomethasone Treatment.

FP/FORM p MDI with AeroChamber and FP pMDI with Volumatic spacer did not affect lower leg growth, measured by knemometry, in asthmatic children, and extra-fine BDP from a breath-actuated inhaler resulted in short-term growth suppression.

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials

Overall for paediatric asthma, FP/FORM and FP/SAL demonstrate a comparable influence on FEVj, asthma symptom scores, sleep disturbance scores, and adverse events.

Real‐life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred‐dose inhalers in patients with asthma treated with ICS/LABA

This study aimed to assess the persistence and effectiveness of switching from DPI to pMDI for inhaled corticosteroid and long‐acting β2‐agonist combination therapy (ICS/LABA).

Avoiding misdiagnosis in patients with dyspnea and wheezing: a case report illustrating the clinical implications of fixation error

A challenging case characterized by the contemporaneous presence of a common disease, asthma, together with a rare respiratory disease, idiopathic tracheal stenosis is reported, confirming the favorable efficacy and safety profile which are reflected in the recommendations of the international guidelines.

A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma

FP/FORM improved lung function and measures of asthma control with comparable efficacy to FP/SAL, and demonstrated a favourable safety and tolerability profile in children aged 4–12 years.



Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial

Results from this study demonstrate that fluticasone/formoterol 250/10 µg b.i.d. provides superior efficacy compared to flutic asone alone for the management of moderate-to-severe asthma, with a safety profile similar to that of fluticAsone monotherapy.

Onset of Bronchodilation with Fluticasone/Formoterol Combination Versus Fluticasone/Salmeterol in an Open-Label, Randomized Study

Fluticasone/formoterol provided a faster onset of bronchodilation than fluticas one/salmeterol, which was maintained over 12 weeks of treatment, and may facilitate treatment adherence among patients with asthma.

Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler.

Fluticasone/Formoterol Combination Therapy versus Budesonide/Formoterol for the Treatment of Asthma: A Randomized, Controlled, Non-Inferiority Trial of Efficacy and Safety

This study demonstrated comparable efficacy of fluticasone/formoterol to budesonide/ formoterol in terms of the primary endpoint, change in pre-dose FEV1 from baseline to Week 12, and comparable results were obtained for both treatment groups for all other secondary endpoints.

Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study

Fluticasone/formoterol was well tolerated and had a good safety profile that was similar to fluticas one/salmeterol, and has a more rapid onset of action, reflecting the faster bronchodilatory effects of formoterol compared with those of salmeterol.

Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations

The incidence of exacerbations in two fixed-dose fluticasone/formoterol studies was low and less than in the majority of comparable published studies involving other ICS/LABA combinations.

Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma.

Fluticasone/formoterol had a good safety and efficacy profile over the 6- and 12-month study periods and the efficacy analyses showed statistically significant improvements at every time point throughout the study period at both doses.

Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial

Fluticasone/formoterol combination therapy had comparable efficacy to its individual components administered concurrently, when measured by post-dose FEV1 in patients aged ≥12 years with mild to moderate–severe asthma, in an open-label, parallel-group, multicentre study.